Ligand id: 7446

Name: ocriplasmin

No information available.
Summary of Clinical Use
Approved to treat symptomatic vitreomacular adhesion.
Mechanism Of Action and Pharmacodynamic Effects
Ocriplasmin can degrade various structural proteins, including laminin and fibronectin, which are localized in the vitreoretinal surface and bind the vitreous humour to the retina [1]. Orciplasmin dissolves abnormally strong bonding between the vitreous humour and retina which can cause pathological vitreomacular traction and subsequent ocular damage.